Fulgent Genetics, Inc. reports results for the quarter ended September 30 - Earnings Summary
Fulgent Genetics, Inc. reports results for the quarter ended September 30 - Earnings Summary
Fulgent Genetics, Inc. FLGT.OQ reported a quarterly adjusted loss of 9 cents per share for the quarter ended September 30, lower than the same quarter last year, when the company reported EPS of 14 cents. The lone analyst forecast for the quarter was for a loss of 65 cents per share.
Revenue rose 115.6% to $-13.15 million from a year ago; analysts expected $86.30 million.
Fulgent Genetics, Inc.'s reported EPS for the quarter was a loss of 48 cents.
The company reported a quarterly loss of $13.15 million.
Fulgent Genetics, Inc. shares had fallen by 10.6% this quarter and lost 25.1% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts was unchanged in the last three months.
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the healthcare facilities & services peer group is "buy."
Wall Street's median 12-month price target for Fulgent Genetics, Inc. is $19.00, about 1.8% below its last closing price of $18.66
This summary was machine generated from LSEG data November 5 at 11:40 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
Sep. 30 2026 | -0.65 | -0.09 | Beat |
Jun. 30 2026 | -0.46 | -0.58 | Missed |
Mar. 31 2026 | -0.10 | -0.36 | Missed |
Dec. 31 2025 | 0.03 | 0.16 | Beat |
Recent news on Fulgent Genetics
See all newsFulgent Genetics, Inc. reports results for the quarter ended September 30 - Earnings Summary
Fulgent Genetics Q3 revenue rises 8% on improved collection rates
Brief: Fulgent Genetics Q3 Revenue USD 90.412 Million
U.S. RESEARCH ROUNDUP-Cloudflare, Replimune, Walmart
Fulgent Genetics Inc reports results for the quarter ended June 30 - Earnings Summary